Hep C News This Week

StephenW

AASLD:   IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects  - (01/31/13)

Phase II all-oral combination studies of Simeprevir (TMC435), TMC647055 (non nuc polymerase inhibitor) and IDX719 (NS5A) for the treatment of Hepatitis C to be initiated shortly - 4 articles below  - (01/31/13)

Hepatitis C cases climbing in NKY......Almost 88 percent (of those tested) had a history of IV drug use......Many of those tested have been in the age group of 20-29  - (01/31/13)

AASLD:  GS-7977 & HIV ARTs PK - No Clinically Significant Pharmacokinetic Interactions Between Sofosbuvir (GS-7977) and HIV Antiretrovirals Atripla, Rilpivirine, Darunavir/Ritonavir, or Raltegravir in Healthy Volunteers - (01/31/13)

        Community Access National Network Launches New Hepatitis Initiative; The "HEPATITIS: Education, Advocacy & Leadership" Project (HEAL) will promote awareness, with a particular focus on HIV and HCV co-infection  - (01/25/13)

New Study: GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation  - (01/25/13)

When Did Phase 3 Studies Begin for TMC435, BI201335, GS7977, BMS790052, and PegLambda and when will they finish & receive FDA approval.  - (01/25/13)

Association of tattooing and hepatitis C virus infection: A multicenter case-control study....authors suggest HCV screening for those with tattoos  - (01/25/13)

HCV Treat Now or Wait?? What's Currently in Phase 3 Now, Drug Development Timeline; Liver Transplant Treatment/Studies; New study in advanced hepatic fibrosis: TMC435+GS7977 (+/-RBV) for treatment-naives & null responders  - (01/22/13)

TMC435+GS7977 (Rbv) New Study in Advanced Hepatic Fibrosis- Null Responders & Naives  - (01/22/13)

How Long Can HCV Survive Outside The Body - "Transmission of Hepatitis C Virus Among People Who Inject Drugs: Viral Stability and Association With Drug Preparation Equipment"  - (01/22/13)

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin....previous reports on telaprevir & boceprevir stopping rules  - (01/22/13)

The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries  - (01/17/13)

Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program  - (01/17/13)

Screening for Hepatitis C Virus Infection in Adults: A Systematic Review for the U.S. Preventive Services Task Force  - (01/16/13)

Comparative Effectiveness of Antiviral Treatment for Hepatitis C Virus Infection in Adults: A Systematic Review  - (01/16/13)

"Hepatitis C may be the serious disease that most combines widespread prevalence with widespread ignorance." - New HCV Policy Paper: "Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' that is Hepatitis C" from Janssen  - (01/16/13)

Economist Intelligence Unit Report Calls for Global Policy Innovation to Tackle the 'Silent Pandemic' that is Hepatitis C - new global HCV policy paper  - (01/15/13)

3rd Intl Wrkshp on HIV & Women: Risk of Progression to Fibrosis Twice Higher in Women Than Men With HCV/HIV - written by Mark Mascolini - (01/15/12)

3rd Intl Wrkshp on HIV & Women: Lower Cognitive Scores in Women With HCV/HIV Than With HIV Alone - written by Mark Mascolini - (01/15/12)

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?  - (01/13/13)

AASLD:  First ever successful use of Daclatasvir and GS-7977 (Sofosbuvir) , an IFN-free regimen, in a Liver Transplant recipient with severe recurrent Hepatitis C - (01/12/13)

        Scientists Discover New Gene That Affects Clearance of Hepatitis C Virus........A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus  - (01/10/13)

Interferon free therapy with direct acting antivirals for HCV  - (01/08/13)

GS-7977 Liver Transplant Studies  - (01/08/13)

AASLD:  The Pharmacokinetic Interaction Between the Investigational NS3/4A HCV Protease Inhibitor TMC435 and Methadone - (01/08/13)

AASLD:  No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus - (01/07/13)

AASLD: No pharmacokinetic interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and an oral contraceptive containing ethinylestradiol and norethindrone - (01/07/13)

Interferon free therapy with direct acting antivirals for HCV  - (01/07/13)

AASLD: No Clinically Significant Pharmacokinetic Drug-Drug Interactions Between Sofosbuvir (GS-7977) and the Immunosuppressants Cyclosporine A or Tacrolimus in Healthy Volunteers  - (01/07/13)

GILEAD PROVIDES UPDATE ON HEPATITIS C DEVELOPMENT PROGRAMS - update on GS-7977+GS-5885+Rbv in null responders in Electron  - (01/07/13)